Lantheus Holdings, Inc. with ticker code (LNTH) have now 8 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 130 and 110 calculating the average target price we see $119.63. Now with the previous closing price of $68.03 and the analysts are correct then we can expect a percentage increase in value of 75.8%. The 50 day moving average now sits at $67.31 and the 200 moving average now moves to $74.99. The company has a market capitalization of 4.46B. The stock price for the company is currently 65.23 USD
The potential market cap would be $7,849,428,979 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 138.79, revenue per share of 16.46 and a 8.4% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
